As part of a new partnership, Partek Flow NGS analysis software will help researchers access single-cell RNA sequences without the need for bioinformatics expertise.
The company acquired GnuBio, which was developing a droplet-based sequencing platform, in 2014 for $39.7 million in cash and $10 million in contingent payments.
The aim of the project, called Metafluidics, is to replace cumbersome conventional approaches with a cheaper, faster, and higher-throughput microfluidics platform.
The technology uses DNAzyme-based sensors, fluorescent biomarkers, and a high-throughput particle counter to rapid identify rare targets in complex raw samples.
After scrapping initial plans to develop a diagnostic instrument, the company has been working for several years to advance its single-cell droplet platform for targeted drug development.
The method simplifies previous techniques, and preliminary testing using a microfluidic device indicates it could ultimately be used in low-resource settings.
The UK's Human Fertility and Embryology Authority calls for consumer genetic testing companies to warn customers that testing could uncover family secrets, according to the Guardian.
